EGFR and non-small cell lung carcinoma: With the advent of molecular biology and immunology, treatment options for NSCLC have expanded, including therapies targeting epidermal growth factor receptor (EGFR) [46]and vascular endothelial growth factor (VEGF) receptors and their ligands [47–49], as well as ICI therapy.